The GSK reformulation induced acceptable immune responses for both influenza A and B strains, overcoming a setback earlier in the ability to successfully neutralize the latter.
The new data amend that from prelicensure trials, which did not include fair representation of older adults and others more vulnerable to severe RSV disease.
The Bridge Access Program allowed Americans who are uninsured or underinsured to receive COVID-19 vaccination at not cost and was ended abruptly last month.